# Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

> **NCT03325556** · PHASE3 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 392 (actual)

## Conditions studied

- Dementia-related Psychosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Pimavanserin 34 mg
- **DRUG:** Pimavanserin 20 mg

## Key facts

- **NCT ID:** NCT03325556
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-10-30
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325556, "Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03325556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*